6-K
Silence Therapeutics plc (SLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2021
Commission File Number: 001-39487
Silence Therapeutics plc
(Exact Name of Registrant as Specified in Its Charter)
72 Hammersmith Road
London W14 8TH
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On April 19, 2021, Silence Therapeutics plc the (“Company”) issued a press release regarding the purchase of American Depositary Shares (“ADSs”), each representing three ordinary shares of the Company, nominal value £0.05 per share, by the following persons at the Company discharging managerial responsibilities. The purchase price was $23.09 per ADS: 4,331 ADSs were purchased by Steven Romano, Non-Executive Director of the Company, 4,331 ADSs were purchased by Michael Davidson, MD, Non-Executive Director of the Company, 217 ADSs were purchased by Dave Lemus, Non-Executive Director of the Company, 6,063 ADSs were purchased by Mark Rothera, Chief Executive Officer and Executive Director of the Company and 8,662 ADSs were purchased by Craig Tooman, Chief Financial Officer of the Company.
A copy of the press release is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.
EXHIBIT INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release, of Silence Therapeutics plc dated April 19, 2021. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SILENCE THERAPEUTICS PLC | |||
|---|---|---|---|
| Date: April 19, 2021 | By: | /s/ Mark Rothera | |
| Name: Mark Rothera | |||
| Title: President and Chief Executive Officer |
sln-ex991_6.htm
Exhibit 99.1
Purchase of American Depositary Shares and PDMR Dealings
19^th^ April 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that, on 16 April 2021 the following purchases of American Depositary Shares ("ADSs"), each representing three ordinary shares of 5 pence each in the capital of the Company (“Ordinary Shares”), were made by persons discharging managerial responsibilities at a purchase price of $23.09 per ADS: 4,331 ADSs were purchased by Steven Romano, Non-Executive Director of the Company, 4,331 ADSs were purchased by Michael Davidson, MD, Non-Executive Director of the Company, 217 ADSs were purchased by Dave Lemus, Non-Executive Director of the Company, 6,063 ADSs were purchased by Mark Rothera, Chief Executive Officer and Executive Director of the Company and 8,662 ADSs were purchased by Craig Tooman, Chief Financial Officer of the Company.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, provide further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | ||
|---|---|---|---|
| a) | Name | Steven Romano | |
| 2. | Reason for the notification | ||
| a) | Position / status | Non-Executive Director | |
| b) | Initial notification / Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Silence Therapeutics plc | |
| b) | LEI | 213800SSURRJBX85SQ91 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument<br><br><br><br><br><br>Identification code | American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc<br><br><br><br><br><br>ISIN for Silence Therapeutics plc ADSs:<br><br><br>US82686Q1013 | |
| b) | Nature of the transaction | Purchase of ADSs in Silence Therapeutics plc | |
| c) | Price(s) and volume(s) | Price | Volume |
| $23.09 | 4,331 |
| d) | Aggregated information<br><br><br>- Aggregated volume<br><br><br>- Price | 4,331 ADSs<br><br><br>$100,002.79 |
|---|---|---|
| e) | Date of the transaction | 16 April 2021 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |
| --- | --- | --- |
| a) | Name | Michael Davidson |
| 2. | Reason for the notification | |
| a) | Position / status | Non-Executive Director |
| b) | Initial notification / Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Silence Therapeutics plc |
| b) | LEI | 213800SSURRJBX85SQ91 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument<br><br><br><br><br><br>Identification code | American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc<br> <br>ISIN for Silence Therapeutics plc ADSs:<br>US82686Q1013 |
| b) | Nature of the transaction | Purchase of ADSs in Silence Therapeutics plc |
| c) | Price(s) and volume(s) | Price |
| 23.09 | ||
| d) | Aggregated information<br><br><br>- Aggregated volume<br><br><br>- Price | 4,331 ADSs<br>100,002.79 |
| e) | Date of the transaction | 16 April 2021 |
| f) | Place of the transaction | Outside a trading venue |
All values are in US Dollars.
| 1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |
|---|---|---|
| a) | Name | Dave Lemus |
| 2. | Reason for the notification | |
| a) | Position / status | Non-Executive Director |
| b) | Initial notification / Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Silence Therapeutics plc |
| b) | LEI | 213800SSURRJBX85SQ91 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
|---|---|---|
| a) | Description of the financial instrument, type of instrument<br><br><br><br><br><br>Identification code | American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc<br> <br>ISIN for Silence Therapeutics plc ADSs:<br>US82686Q1013 |
| b) | Nature of the transaction | Purchase of ADSs in Silence Therapeutics plc |
| c) | Price(s) and volume(s) | Price |
| 23.09 | ||
| d) | Aggregated information<br><br><br>- Aggregated volume<br><br><br>- Price | 217 ADSs<br>5,010.53 |
| e) | Date of the transaction | 16 April 2021 |
| f) | Place of the transaction | Outside a trading venue |
All values are in US Dollars.
| 1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |
|---|---|---|
| a) | Name | Mark Rothera |
| 2. | Reason for the notification | |
| a) | Position / status | Chief Executive Officer and Executive Director |
| b) | Initial notification / Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Silence Therapeutics plc |
| b) | LEI | 213800SSURRJBX85SQ91 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument<br><br><br><br><br><br>Identification code | American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc<br> <br>ISIN for Silence Therapeutics plc ADSs:<br>US82686Q1013 |
| b) | Nature of the transaction | Purchase of ADSs in Silence Therapeutics plc |
| c) | Price(s) and volume(s) | Price |
| 23.09 | ||
| d) | Aggregated information<br><br><br>- Aggregated volume<br><br><br>- Price | 6,063 ADSs<br>139,994.67 |
| e) | Date of the transaction | 16 April 2021 |
| f) | Place of the transaction | Outside a trading venue |
All values are in US Dollars.
| 1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |
|---|---|---|
| a) | Name | Craig Tooman |
| 2. | Reason for the notification | |
| a) | Position / status | Chief Financial Officer |
| b) | Initial notification / Amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Silence Therapeutics plc |
| b) | LEI | 213800SSURRJBX85SQ91 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument<br><br><br><br><br><br>Identification code | American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc<br> <br>ISIN for Silence Therapeutics plc ADSs:<br>US82686Q1013 |
| b) | Nature of the transaction | Purchase of ADSs in Silence Therapeutics plc |
| c) | Price(s) and volume(s) | Price |
| 23.09 | ||
| d) | Aggregated information<br><br><br>- Aggregated volume<br><br><br>- Price | 8,662 ADSs<br>200,005.58 |
| e) | Date of the transaction | 16 April 2021 |
| f) | Place of the transaction | Outside a trading venue |
All values are in US Dollars.
Enquiries:
| Silence Therapeutics plc<br><br><br>Gem Hopkins, Head of IR & Corporate Communications | Tel: +1 (646) 637-3208 |
|---|---|
| Investec Bank plc (Nominated Adviser and Broker)<br><br><br>Daniel Adams/Gary Clarence | Tel: +44 (0) 20 7597 5970 |
| European PR<br><br><br>Consilium Strategic Communications<br><br><br>Mary-Jane Elliott/Chris Welsh/Angela Gray<br><br><br>[email protected] | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes
in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.